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Macrophages play critical, but opposite roles, in acute and chronic inflammation and 10	
cancer1-5. In response to pathogens or injury, inflammatory macrophages express 11	
cytokines that stimulate cytotoxic T cells, while highly abundant macrophages in 12	
neoplastic and parasitic diseases express anti-inflammatory cytokines that induce 13	
immune suppression and may promote resistance to T cell checkpoint inhibitors1-7. Here 14	
we show that macrophage PI(3)Kinase γ controls a critical switch between immune 15	
stimulation and suppression during inflammation and cancer. PI3Kγ signaling through 16	
Akt and mTor inhibits NFκB activation while stimulating C/EBPβ activation, thereby 17	
inducing a transcriptional program that promotes immune suppression during 18	
inflammation and tumor growth. In contrast, selective inactivation of macrophage PI3Kγ 19	
stimulates and prolongs NFκB activation and inhibits C/EBPβ activation, thus promoting 20	
an immunostimulatory transcriptional program that restores CD8+ T cell activation and 21	
cytotoxicity and synergizes with checkpoint inhibitor therapy to promote tumor 22	
regression and extend survival in mouse models of cancer. As PI3Kγ-directed, anti-23	
		 2	
inflammatory gene expression predicted survival probability in cancer patients, our 1	
findings demonstrate that therapeutic targeting of intracellular signaling pathways that 2	
regulate the switch between macrophage polarization states can control immune 3	
suppression in cancer and other disorders. 4	
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We investigated the association between immune responses and survival in primary 1	
tumors from HPV+ (n=97) and HPV- (n=423) head and neck squamous cell carcinoma 2	
(HNSCC) cohorts from TCGA.8 High expression levels of pro-inflammatory mRNAs 3	
IL12A, IL12B, IFNG, and CD8A were associated with increased survival in HPV+ but 4	
not HPV- cohorts, while high expression of IL6 was negatively associated with survival 5	
(Extended Data Fig. 1a-e). HPV+ patients with this favorable immune expression profile 6	
(n=35) had 97% survival at 3 years compared with 57% survival for patients without this 7	
profile (n=62) (Fig. 1a). Similar associations were observed in lung adenocarcinoma and 8	
gastric carcinoma patients (Extended Data Fig. 1f-g). These results suggested that 9	
therapeutic approaches that stimulate pro-inflammatory gene expression might enhance 10	
cancer patient survival. 11	
 12	
We suspected that macrophage signaling pathways, such as those regulated by Class 13	
IB isoform PI3Kγ, might control the switch between immune stimulation and suppression 14	
in inflammation and cancer. PI3Kγ is abundantly expressed in myeloid but not cancer 15	
cells (Extended Data Fig. 1h)9-12 and promotes myeloid cell trafficking during 16	
inflammation and cancer11-15. Mice lacking PI3Kγ (p110γ-/-) mounted exaggerated, 17	
macrophage-mediated pro-inflammatory responses upon exposure to pathogenic stimuli 18	
(Fig. 1b; Extended Data Fig. 1i-k), suggesting that PI3Kγ inhibits macrophage 19	
inflammatory responses and might do so in the tumor microenvironment. Mice lacking 20	
PI3Kγ and mice that were treated with PI3Kγ antagonists (TG100-11512 or IPI-54916) 21	
exhibited significantly suppressed growth of implanted HPV+ (MEER) and HPV- 22	
(SCCVII) HNSCC, lung carcinoma (LLC), and breast carcinoma (PyMT) tumors (Fig. 23	
		 4	
1c). PI3Kγ inhibition did not directly affect the growth or survival of tumor cells, which do 1	
not express the kinase (Extended Data Fig. 1h, 1l-m)12-15. PI3Kγ inhibition suppressed 2	
long-term growth and metastases of spontaneous breast tumors, extended survival of 3	
mice with orthotopic breast tumors and enhanced the sensitivity of tumors to the 4	
nucleoside analogue gemcitabine (Fig. 1d; Extended Data Fig. 1n-q). While PI3Kγ 5	
inhibition did not affect the accumulation of CD11b+Gr1-F4/80+ tumor-associated 6	
macrophages (TAMs) in tumors (Extended Data Fig. 2a-f), it enhanced expression of 7	
MHCII and pro-inflammatory cytokines and inhibited expression of immune suppressive 8	
factors in tumors and TAMs, indicating that PI3Kγ controls the TAM switch between 9	
immune suppression and immune stimulation (Fig.1e-g Extended Data Fig. 2g-j, 3a-f).  10	
 11	
To determine whether PI3Kγ directly regulates macrophage polarization, we analyzed 12	
mRNA and protein expression in primary murine macrophages stimulated in vitro with 13	
basal (CSF-1), pro-inflammatory (IFNγ/LPS + CSF-1) or anti-inflammatory (IL-4 + CSF-14	
1) conditions. Pro-inflammatory stimuli upregulate macrophage expression of innate 15	
immune proteins, cytokines and cell surface receptors, while anti-inflammatory stimuli 16	
induces expression of immunosuppressive factors similar to those expressed in TAMs 17	
(Extended Data Fig. 4a-c)1. Genes and proteins associated with immune activation, 18	
antigen-presentation and T cell activation were upregulated In p110γ-/- and PI3Kγ 19	
inhibitor-treated macrophages (Fig. 2a-c, Extended Data Fig. 4c-f, 5a-g). In contrast, 20	
genes associated with immune suppression and chemoattraction were inhibited (Fig. 21	
2a-c, Extended Data Fig. 4c-f, 5a-g). These results confirm that PI3Kγ controls a 22	
macrophage switch between immune stimulation and suppression.  23	
		 5	
 1	
To identify how PI3Kγ regulates macrophage immune responses, we evaluated 2	
DNA binding activities of NFκB p65 RelA and the C/CAAT enhancer binding protein 3	
C/EBPβ in WT and p110γ null macrophages, as NFκB promotes expression of 4	
inflammatory cytokines17, while C/EBPβ promotes expression of the 5	
immunosuppressive factor Arg1.18-19 PI3Kγ ablation rapidly and sustainably stimulated 6	
RelA DNA binding activity in macrophages (Fig. 2d, Extended Data Fig. 5h). In contrast, 7	
PI3Kγ ablation suppressed DNA binding activity of C/EBPβ (Fig. 2e). Consistent with 8	
these findings, PI3Kγ inhibition stimulated and sustained p65 RelA phosphorylation and 9	
simultaneously inhibited C/EBPβ and Akt phosphorylation (Fig. 2f-g, Extended Data Fig. 10	
6a-b).  11	
 12	
We next examined the effect of PI3Kγ inhibition on the stability and phosphorylation of 13	
proteins that activate NFκB, including the TLR4-associated adaptor protein IRAK-1 and 14	
inhibitory kappa B kinase β, IKKβ, which promotes degradation of IκBα, with 15	
subsequent release of NFκB from an inhibitory IκB-NFκB complex17. PI3Kγ deletion 16	
enhanced phosphorylation of IKKβ and TBK1 and degradation of IRAK-1 and IκBα in 17	
LPS-stimulated p110γ-/- macrophages (Fig. 2h). As an IKKβ inhibitor suppressed the 18	
inflammatory phenotype observed in p110γ-/- macrophages (Fig. 2i), these results 19	
indicate PI3Kγ is both a feedback inhibitor of the TLR4-NFκB activation pathway and a 20	
promoter of IL-4 and C/EBPβ signaling.  21	
 22	
		 6	
C/EBPβ has been previously linked with tumor immune suppression through its control 1	
of Arg-1 expression18-19. Expression of constitutively activated PI3Kγ (p110γCAAX)11 2	
was sufficient to induce Arg-1 expression, in a manner that was inhibited by Cebpb, 3	
Mtor, or S6ka knockdown (Extended Data Fig. 6c-d). Cebpb knockdown as well as 4	
inhibitors of S6K and mTOR suppressed expression of immune suppressive factors and 5	
stimulated expression of pro-inflammatory cytokines (Extended Data Fig. 6e-g). These 6	
results show that PI3Kγ promotes immune suppression by activating mTor-S6Kα-7	
C/EBPβ and inhibiting NFκB, thereby controlling a switch that regulates the balance 8	
between immune suppression and stimulation. 9	
 10	
Since PI3Kγ blockade stimulates pro-inflammatory responses in macrophages, we 11	
asked whether macrophage PI3Kγ blockade promotes adaptive immunity. TAMs were 12	
isolated from WT and p110γ-/- tumors, mixed with tumor cells and adoptively transferred 13	
into new WT or p110γ-/- recipient mice (Fig. 3a). Tumor growth was significantly 14	
inhibited in tumors containing p110γ-/- TAMs but not WT TAMs (Fig. 3b). CD8+ T cells 15	
were significantly increased in tumors with p110γ-/- but not WT macrophages (Fig. 3c, 16	
Extended Date Fig. 6h), indicating that PI3Kγ signaling in TAMs inhibits CD8+ T cell 17	
recruitment to tumors. To determine whether macrophage-derived cytokines control 18	
tumor growth, we implanted tumor cells mixed with in vitro cultured macrophages or 19	
conditioned medium (CM) into WT mice. Tumor growth was enhanced by IL-4 20	
stimulated WT macrophages and CM but inhibited by IL-4 stimulated p110γ-/- 21	
macrophages and CM from p110γ-/- or PI3Kγ inhibitor-treated macrophages and by all 22	
LPS-stimulated macrophages and CM (Fig. 3d-e). To determine which macrophage-23	
		 7	
derived immune factors affect tumor growth in vivo, we treated WT and p110γ-/- TAMs 1	
ex vivo with inhibitors of mTor, Arginase, IKKβ, IL-12 or NOS2 prior to mixing with tumor 2	
cells and implanting in mice (Extended Data Fig. 6i). Blockade of mTOR or Arginase in 3	
WT macrophages suppressed tumor growth, while inhibition of NOS2, IL-12 or IKKβ in 4	
p110γ-/- macrophages stimulated tumor growth. These results indicate that PI3Kγ-5	
mTOR mediated immune suppression promotes tumor growth and that PI3Kγ inhibition 6	
reverses these effects by shifting macrophages toward NFκβ-dependent pro-7	
inflammatory polarization. 8	
 9	
To confirm that macrophage PI3Kγ controls tumor growth, mice bearing pre-established 10	
tumors were treated with PI3Kγ inhibitors in combination with clodronate liposomes, 11	
which deplete macrophages from tissues.20 PI3Kγ inhibitor and clodronate liposome 12	
treatment each partially inhibited tumor growth and stimulated T cell recruitment, but the 13	
combination had no additive effects, confirming that PI3Kγ in macrophages, rather than 14	
other cell types, promotes tumor growth (Extended Data Fig. 7a-d). Similar results were 15	
noted when CSF1R inhibition21 and PI3Kγ inhibition were combined (Extended Data Fig. 16	
7e-f).  17	
 18	
PI3Kγ blockade stimulated T cell recruitment into tumors, as total and CD8+ T cell 19	
content increased in tumors from p110γ-/- mice without significantly altering systemic T 20	
cell content (Fig. 3f; Extended Data Fig. 7g-i). PI3Kγ inhibition did not suppress tumor 21	
growth in CD8 null or antibody-depleted mice, suggesting PI3Kγ inhibition blocks tumor 22	
		 8	
growth by recruiting and/or activating CD8+ T cells (Fig. 3g, Extended Data Fig. 7j-k). 1	
When T cells were isolated from tumor-bearing or naive animals, mixed with tumor cells 2	
and implanted in mice, only T cells from p110γ-/- tumor-bearing animals suppressed 3	
tumor growth (Fig. 3h). However, PI3Kγ inhibition did not directly activate T cells, as 4	
neither PI3Kγ deletion nor treatment of T cells with PI3Kγ inhibitors ex vivo affected T 5	
cell proliferation or activation; in contrast, PI3Kδ inhibition suppressed T cell activation in 6	
vitro and promoted tumor growth in vivo (Fig. 3i; Extended Data Fig. 7l-m, 8a-b). PI3Kγ 7	
inhibition promoted T cell mediated cytotoxicity, as T cells isolated from p110γ-/- or 8	
PI3Kγ inhibitor-treated tumors stimulated tumor cell cytotoxicity (Extended Data Fig. 8c-9	
g). T cells from p110γ-/- or PI3Kγ inhibitor-treated animals expressed significantly more 10	
IFNγ and Granzyme B and significantly less TGFβ1 and IL10 protein and mRNA than T 11	
cells from WT animals (Fig. 3j; Extended Data Fig. 8h-l). Together, these results 12	
indicate that macrophage PI3Kγ inhibition indirectly promotes both Th1 and cytotoxic 13	
adaptive immune responses.  14	
 15	
To determine whether PI3Kγ inhibition interacts with other immune therapies, we 16	
combined PI3Kγ and the checkpoint inhibitor anti-PD-1 in mouse tumor models. PD-L1, 17	
but not PD-L2, was expressed on macrophages in vitro and in vivo (Extended Data Fig. 18	
9a-b). PI3Kγ inhibition synergized with anti-PD-1 to suppress the growth of HPV+ 19	
HNSCC tumors in p110γ-/- or inhibitor-treated male or female animals, inducing tumor 20	
regression in 86% of male and 90-100% of female animals, as well as continuous 21	
survival to date in 60% of male mice and 90-100% of female mice (Fig. 4a-c, Extended 22	
Data Fig. 9c-d). Importantly, PI3Kγ inhibition also synergized with anti-PD-1 to reduce 23	
		 9	
tumor growth, extending survival and inducing tumor regression in 30% of mice bearing 1	
HPV- HNSCC (SCCVII) tumors (Fig. 4d-f, Extended Data Fig. 9e). The combination of 2	
PI3Kγ and anti-PD-1 inhibitors activated T cell memory, as 100% of mice that had 3	
previously cleared HPV+ tumors efficiently suppressed re-challenge with HPV+ tumor 4	
cells and remained cancer free (Extended Data Fig. 9f). PI3Kγ and PD-1 inhibitors each 5	
stimulated immune response gene expression and inhibited immune suppressive gene 6	
expression, MHCII expression in TAMs, and CD8+ T cell recruitment to tumors; 7	
combination therapy further elevated these parameters (Fig. 4g-i, Extended Data Fig. 8	
9g). These studies show that PI3Kγ inhibition can synergize with T cell targeted therapy 9	
to promote anti-tumor immune responses that induce sustained tumor regression in 10	
murine models of cancer. 11	
 12	
PI3Kγ-regulated immune responses might also affect outcome in cancer patients. We 13	
identified 43 PI3Kγ-regulated genes that significantly associated with survival in TCGA 14	
HPV+ HNSCC patients (Fig. 5j). HPV+ HNSCC patients with a low PI3Kγ activity profile 15	
experienced 100% survival at 3 years, compared with 56% survival for the remaining 63 16	
patients (Fig. 5k). In HPV- HNSCC patients, 39 of these genes were significantly shifted 17	
in the direction of high PI3Kγ activity, consistent with a pattern of pervasive immune 18	
suppression and reduced survival in HPV- disease (Extended Data Fig. 10a). In lung 19	
adenocarcinoma patients, 18 genes predicted survival; patients with a low  PI3Kγ 20	
activity profile had 73% survival at 3 years, compared with 55% survival for others 21	
(Figure 5l). These results suggest that a PI3Kγ-regulated immune suppression signature 22	
		 10	
is associated with survival in cancer patients and that PI3Kγ inhibitors might provide 1	
clinical benefit in cancer patients.  2	
 3	
Here we have shown that PI3Kγ regulates innate immunity during inflammation and 4	
cancer (Extended Data Fig.10b-c). Prior studies have implicated PI3Ks in the regulation 5	
of pro-inflammatory immune responses in macrophages, as pan-PI3K inhibitors and null 6	
mutations in the PI3Kγ effectors PDK1, Akt1 and TSC enhanced pro-inflammatory NFκB 7	
dependent transcription in macrophages,22-24 while inhibition of PTEN and SHIP, which 8	
oppose PI3Kinase function, promotes immune suppression.25-26 As macrophage 9	
reprogramming can enhance the activity of checkpoint inhibitors in cancer5,13,21,27, our 10	
studies indicate that inhibitory targeting of macrophage signaling pathways may provide 11	
novel approaches to improve the long-term survival of cancer patients.  12	
 13	
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Figure 1: PI3Kγ  promotes immune suppression. (a) Multivariate immune response 1	
mRNA signature in HPV+ HNSCC patients (n=97). (b) Immune response mRNA 2	
expression in p110γ-/- or WT peritoneal macrophages (n=3). (c) Mean +/- sem tumor 3	
growth in WT, p110γ-/- and PI3Kγ-inhibitor-treated mice (n=15). Arrow, daily treatment 4	
initiation. (d-f) Mean +/- sem (d) spontaneous breast carcinoma growth and metastasis 5	
(bar, 200µm) in WT (n=21) and p110γ-/- (n=8) animals; (e) MHCII expression on WT vs 6	
p110γ-/- TAMs (n=3) and (f) fold change mRNA expression in tumors and tumor-derived 7	
CD11b+ cells from p110γ-/- and PI3Kγ inhibitor-treated mice (n=5). (g) Heatmap of 8	
immune response mRNA expression in tumors from WT and p110γ-/- mice (n=3). 9	
n=biological replicates. 10	
 11	
Figure 2: PI3Kγ  regulates NFκB and C/EBPβ during macrophage polarization. (a) 12	
Heatmap of mRNA expression in p110γ-/- vs WT macrophages (n=3). (b-c) Mean +/- 13	
sem (b) mRNA (n=3) and (c) protein (n=4) expression. (d-e) Mean +/- sem (d) p65 RelA 14	
and (e) C/EBPβ DNA-binding activity in WT and p110γ-/- macrophages (n=4). (f-g) 15	
Immunoblotting of pRelA/RelA, pC/EBPβ/C/EBPβ, and pAkt/Akt in (f) LPS and (g) IL-4 16	
stimulated WT and p110γ-/- macrophages. (h) Immunoblotting of IRAK1, pIKKβ/IKKβ, 17	
IκBα, pTBK1/TBK1, p110γ and actin in WT and p110γ-/- macrophages. (i) Mean +/- sem 18	
mRNA expression in IKKβ inhibitor-treated macrophages (n=3). n=biological replicates. 19	
 20	
Figure 3: Macrophage PI3Kγ  suppresses T cell activation. (a) Adoptive transfer 21	
method. (b) Weights of tumors implanted with p110γ-/-, WT or no TAMs (n=8). (c) CD8+ 22	
		 13	
T cells from b (n=16). (d, e) Weights of tumors implanted with (d) in vitro cultured 1	
macrophages (n=8) or (e) macrophage-conditioned medium (CM) (n=8). (f) Percent T 2	
cells in WT and p110γ-/- tumors (n=3). (g) Tumor volumes in p110γ and/or CD8-/- mice 3	
(n=6). (h-i) Weights of tumors implanted with (h) naïve or tumor-derived T cells (n=8) or 4	
(i) inhibitor-treated T cells (n=16). (j) IFNγ and Granzyme B expression in tumors and T 5	
cells from WT and p110γ-/- animals (n=3). All graphs show mean +/- sem of biological 6	
replicates. 7	
 8	
Figure 4:  PI3Kγ  inhibition synergizes with anti-PD-1. (a, d) Mean +/- sem tumor 9	
volumes in anti-PD-1 (black arrows) treated (a) WT or p110γ-/- mice with HNSCC HPV+ 10	
tumors (n=13) and (d) PI3Kγ inhibitor-treated mice with HPV- HNSCC tumors (n=13). (b, 11	
e) Percent survival of mice in a, d. (c, f) Change in tumor volumes in a, d. (g-h) 12	
Heatmap (g) and graph (h) of mRNA expression from d (n=3). (i) Immune cell profiles 13	
from d. (j) Heatmap of PI3Kγ-regulated mRNA expression in HPV+HNSCC patients 14	
(n=45). (k-l) Multivariate PI3Kγ-regulated immune signature in (k) HPV+HNSCC patients 15	
(n=97) and (l) lung adenocarcinoma patients (n=507). n=biological replicates.  16	
		 14	
METHODS 1	
  2	
Immune-related gene expression signature analysis in TCGA data 3	
 We analyzed TCGA data for association between mRNA expression level of 4	
sixteen candidate immune-related genes (ARG1, IL10, FOXP3, CD68, IL12A, IL12B, 5	
IFNG, CD8A, CD4, CD11B, CD14, TNFA, IL1A, IL1B, IL6 and CCL5) and 5-year overall 6	
survival. Illumina HiSeq RNAseqV2 mRNA expression and clinical data for 520 Head 7	
and Neck squamous cell carcinoma samples were downloaded from the TCGA data 8	
portal. Median follow-up from diagnosis was 1.8 years with range 0.01 years to 17.6 9	
years.   Follow-up time was truncated at 5-years for analysis and 200 deaths occurred 10	
in this period. For each of the 16 candidate immune response genes, we scored 11	
subjects as above (high) or below (low) the median expression and compared survival 12	
using a log rank test at 5% significance. HPV+ patients were stratified into a favorable 13	
immune profile if they had expression above the median for the significant genes IL12A, 14	
IL12B IFNG, CD8A and below the median for IL6.  Kaplan-Meier curves were plotted for 15	
these two groups. Similar methods were used to examine association of these 16 genes 16	
with 720 lung adenocarcinoma, and 876 gastric carcinoma samples using the publically 17	
available data from KM Plotter28. In lung adenocarcinoma, 12 genes were significantly 18	
associated with survival; patients were scored as having a favorable immune profile if 7 19	
or more of the 12 significant genes had expression in the favorable direction. In 876 20	
gastric cancer samples, 8 genes were significantly associated with survival. patients 21	
were scored as having a favorable immune profile if 5 out of the 8 genes had 22	
expression in the favorable direction. 23	
		 15	
 1	
PI3Kγ−regulated gene expression signature analysis in TCGA data 2	
We investigated 66 immune-related genes in four functional classes (17 genes 3	
related to antigen presentation (HLA class I and II molecules), 24 genes surveying T cell 4	
activation, 20 innate immune response genes (IL6, CCL7 and others), and 5 genes 5	
related to cancer cell signaling) that changed expression in response to PI3Kγ inhibition 6	
for association with survival in HPV+ and HPV- TCGA HNSCC and lung 7	
adenocarcinoma cohorts. Within each cancer type, we scored subjects as above or 8	
below the median expression for each gene and compared survival using a log rank 9	
test, using 10% FDR within each class as the significance threshold. HPV+ and HPV- 10	
HNSCC survival were investigated separately, as HPV- HNSCC has generally worse 11	
prognosis.  Within each cohort, patients were classified as having a favorable PI3Kγ  12	
immune response profile if they had expression levels above or below the median in the 13	
direction of low PI3Kγ activity for the genes identified as significant.  We compared the 14	
survival experience of favorable vs less-favorable patients using Kaplan-Meier curves.  15	
Out of the 66 experimentally identified PI3Kγ regulated genes 43 showed significant 16	
association with overall survival in the HPV+ cohort (FDR<10% within each functional 17	
class). Comparison of these genes between HPV+ and HPV- cohort showed that HPV- 18	
samples generally had significantly (p<0.05) lower expression of 42 genes in the 19	
antigen presentation and T cell activation classes, consistent with a pattern of adaptive 20	
immune suppression, and higher expression of genes in the innate immune response 21	
and cancer cell signaling class, which were negatively associated with survival. Only 22	
Malt1 was not differentially expressed between the two groups (p=0.7).  23	
		 16	
 1	
Mice 2	
Pik3cg-/- (p110γ-/-) and Pik3cg-/-; PyMT animals were generated as previously 3	
described12. Cd8-/- and Cd4-/- animals in the C57Bl6 background were purchased from 4	
the Jackson Laboratory, Bar Harbor, ME and crossed with syngeneic Pik3cg-/- animals. 5	
All animal experiments were performed with approval from the Institutional Animal Care 6	
and Use Committee of the University of California, San Diego, La Jolla, CA. Animal 7	
were euthanized before the maximum IACUC allowable tumor burden of 2 cm3/mouse 8	
was exceeded.  9	
 10	
Tumor studies 11	
Wildtype or p110γ-/- 6-8 week-old female or male syngeneic C57Bl/6J (LLC lung, 12	
PyMT breast, and MEER HPV+ HNSCC) or C3He/J (SSCVII HPV- HNSCC) mice were 13	
implanted with 1x106 tumor cells by subcutaneous injection (LLC, MEER, SCCVII) or by 14	
orthotopic injection (PyMT) (n=10-15) and tumor growth was monitored for up to 30 15	
days. Tumor dimensions were measured once when tumors were palpable. Tumor 16	
volumes were calculated using the equation (l2 x w)/2. In some studies, WT and p110γ-17	
/- animals with LLC tumors were treated with gemcitabine (150 mg/kg) or saline by i.p 18	
injection on d7 and d14 (n=10). LLC were acquired from ATCC, PyMT were from Lesley 19	
Ellies (University of California, San Diego), HPV+ MEER were from John Lee (Cancer 20	
Biology Research Center, Sanford Research/USD, Sioux Falls, SD) and SCCVII 21	
squamous carcinoma cells were from Stephen Schoenberger (La Jolla Institute for 22	
Allergy and Immunology). All cell lines were tested for mycoplasma and mouse 23	
		 17	
pathogens and checked for authenticity against the International Cell Line 1	
Authentication Committee (ICLAC; http://iclac.org/databases/cross-contaminations/) list. 2	
 In some studies, mice bearing LLC, PyMT, HPV+ MEER or HPV- HNSCC tumor 3	
cells were treated once daily by oral gavage with vehicle (5%NMP/95% PEG 400), 4	
15mg/kg/day of the PI3Kγ inhibitor IPI-549 or by i.p. injection with 2.5 mg/kg b.i.d of 5	
TG100-1159,43 beginning on day 8 post-tumor injection and continuing daily until 6	
sacrifice. IPI-549 is an orally bioavailable PI3Kγ inhibitor with a long plasma half-life and 7	
a KD value of 0.29 nM for PI3Kγ with >58-fold weaker binding affinity for the other Class 8	
I PI3K isoforms26. Enzymatic and cellular assays confirmed the selectivity of IPI-549 for 9	
PI3Kγ (>200-fold in enzymatic assays and >140-fold in cellular assays over other Class 10	
I PI3K isoforms26. To study the effect of IPI-549 on lung tumor growth, LLC tumor cells 11	
were passaged three times in C57/BL6 Albino male mice. When tumor volume reached 12	
1500 mm3, tumors were harvested and single-cell suspensions were prepared. This 13	
tumor brei inoculum was implanted subcutaneously in the hind flank of C57/BL6 Albino 14	
male mice at 1x106 cells/ mouse. Prior to initiating treatment with once daily IPI-549 (15 15	
mg/kg p.o.), groups were normalized on the basis of tumor volume. In some studies, 16	
WT and p110γ-/- tumor-bearing mice were treated with 100µg of anti-CD8 (clone YTS 17	
169.4) or isotype control clone (LTF-2) from BioXCell administered by i.p. injections on 18	
day 7, 10 and 13 of tumor growth. For all tumor experiments, tumor volumes and 19	
weights were recorded at sacrifice.  20	
 21	
Anti-PD-1 tumor studies 22	
		 18	
C57Bl/6J (wildtype) or p110γ-/- 6-8 week-old male or female mice (MEER HPV+ 1	
HNSCC) or C3He/J (SCCVII HPV- HNSCC) were implanted with tumor cells by 2	
subcutaneous injection (1 x 106 MEER or 1 x 105 SCCVII). In HPV+ MEER studies, 3	
wildtype and p110γ-/- animals were treated with 4 doses of 250 µg of anti-PD-1 antibody 4	
(Clone RMP-14, Bioxcell) or Rat IgG2a isotype control (Clone2A3, Bioxcell) every 3 5	
days starting when tumors became palpable on day 11 (n = 12-14 mice per group). 6	
Wildtype mice bearing HPV+ tumors were also treated with the p110γ inhibitor TG100-7	
11543 b.i.d. by i.p. injection, beginning on day 11. Tumor regressions were calculated as 8	
a percentage of the difference in tumor volume between the date treatment was initiated 9	
and the first date of sacrifice of the control group. For HPV-SCCVII studies, C3He/J 10	
mice were treated with PI3Kγ inhibitor (2.5mg/kg TG100-115 i.p.) beginning on day 6 11	
post-tumor inoculation and with 6 doses of anti-PD-1 antibody (250µg Clone RMP-14, 12	
Bioexcell) or Rat IgG2a isotype control Clone 2A3, Bioxcell) every 3 days beginning on 13	
day 3 (n=12 mice per group) or with a combination of the two. Alternatively, mice were 14	
treated with 5mg/kg TG100-115 b.i.d. +/- anti-PD-1 (250µg every 3 days) beginning on 15	
day 1 (Figure 4). Mice that completely cleared HPV+ MEER tumors were re-injected 16	
with HPV+ tumor cells contralateral to the initial tumor injection and tumor growth was 17	
monitored.	18	
 19	
PyMT models of mammary carcinoma 20	
The growth and metastasis of spontaneous mammary tumors in female PyMT+ (n=13) 21	
and p110γ-/- PyMT+ (n=8) animals was evaluated over the course of 0-15 weeks. Total 22	
tumor burden was determined by subtracting the total mammary gland mass in PyMT- 23	
		 19	
animals from the total mammary gland mass in PyMT+ animals. Lung metastases were 1	
quantified macroscopically and microscopically in H&E tissue sections at week 15.  2	
 3	
LPS induced septic shock 4	
Septic shock was induced in WT and p110γ-/- mice via intraperitoneal injection of 25 5	
mg/kg LPS (Sigma, B5:005). Survival was monitored every 12h and liver, bone marrow 6	
and serum were collected 24h post LPS injection.  7	
 8	
Macrophage depletion studies 9	
C57Bl/6J female mice were implanted with 1 x 106 LLC tumor cells by subcutaneous 10	
injection. When the average tumor size was 250 mm3, mice were treated by i.p. 11	
injection with 1 mg/mouse clodronate or control liposomes (Clodronateliposomes.com, 12	
Amsterdam, The Netherlands) every 4 days for 2 weeks in combination with daily 13	
administration of vehicle or IPI-549 (15 mg/kg/day p.o.). In other studies, six week old 14	
female BALB/c mice were injected subcutaneously with 2.5x105 CT26 murine colon 15	
carcinoma cells in 100µl PBS into the right flank. Eight days later, tumor-bearing mice 16	
were arranged into four groups (n=15) with an average tumor volume of 70mm3. Oral 17	
administration of IPI-549 (15mg/kg) or Vehicle (5%NMP/95% PEG 400) and anti-CSF-18	
1R antibody (50mg/kg i.p. 3x per week, Clone AFS98, Bioexcell) began on day 8 post-19	
tumor injection via gavage at a 5 mL/kg dose volume and continued daily for a total of 20	
18 doses.  21	
 22	
Tumor infiltrating myeloid cell analysis 23	
		 20	
Six week old female BALC/c mice were injected subcutaneously with 2.5x105 CT26 1	
murine colon carcinoma cells in 100µl PBS into the right flank. On day 8 post tumor 2	
injection, tumor-bearing animals were grouped and treated with IPI-549 (15 mg/kg, QD, 3	
PO) or Vehicle (5%NMP/95% PEG 400). In addition, mice were injected i.p. with 4	
50mg/kg anti-CD115 (BioXcell Clone: AFS98 Cat: BE0213) or 50mg/kg rat IgG2a 5	
isotype control (BioXcell Clone: 2A3 Cat: BE0089-R005) antibodies as described above 6	
for a total of three injections. Two days after the final injection animals were euthanized, 7	
tumors were digested in a mixture of 0.5 mg/ml Collagenase IV and 150 U/ml DNAse I 8	
in RPMI-1640 for 30 minutes at 37°C, and tumor-infiltrating myeloid cells were analyzed 9	
by flow cytometry.    10	
 11	
In vivo macrophage adoptive transfer experiments 12	
CD11b+Gr1- cells were isolated from single cell suspensions of LLC tumors from donor 13	
mice by FACS sorting or serial magnetic bead isolation. Additionally, for some 14	
experiments, primary bone marrow derived macrophages were polarized and harvested 15	
into a single cell suspension. Purified cells were admixed 1:1 with LLC tumor cells and 5 16	
x 105 total cells were injected subcutaneously into new host mice. Tumor dimensions 17	
were measured 3 times per week beginning on day 7. In antibody blocking studies, 18	
CD11b+Gr1- cells were incubated with 5 µg of anti-IL-12 clone RD1-5D9 or isotype 19	
clone LTF-2 (BioXCell) for 30 min prior to the addition of tumor cells. Mice were 20	
additionally treated intradermally with 5µg of antibody 3 and 6 days after tumor cell 21	
inoculation. In some studies, CD11b+Gr1- cells were pre-incubated with inhibitors of 22	
Arginase (nor-NOHA, 50 µM, Cayman Chemical), iNOS (1400W dihydrocholoride, 100 23	
		 21	
µM, Tocris), mTOR (rapamycin, 10 µM Calbiochem), or IKKβ (ML120B, 30 µM, Tocris) 1	
for 30 min before the addition of tumor cells. Inoculated mice were further treated by 2	
intradermal injection with inhibitors at 3 and 6 days post inoculation.  3	
 4	
T-cell adoptive transfer 5	
Donor C57Bl/6J (wildtype) or p110γ-/- mice were implanted with 1 x 106 LLC tumor cells 6	
by subcutaneous injection. On day 14 after tumor implantation, CD90.2+, CD4+ or 7	
CD8+ cells were harvested by magnetic bead isolation (Miltenyi Biotec). T cells were 8	
mixed 1:1 with viable LLC tumor cells. Cell mixtures containing 5 x 105 total cells were 9	
injected into the flanks of naïve WT or p110γ-/- mice (n=8-10 per group). Tumor growth, 10	
intratumoral apoptosis and necrosis were investigated over 0-16 days. In other studies, 11	
WT T cells were incubated at 37°C/5% CO2 for 6h with 10 or 100 nM IPI-549 (Infinity 12	
Pharmaceuticals) or Cal-101 (Selleck Chem).  After 6h, T cells were washed, admixed 13	
1:1 with LLC tumor cells, and 1 x 106 total cells were injected subcutaneously into 14	
recipient mice. Tumor growth, was monitored for 14 days. 15	
 16	
Isolation of single cells from murine tumors 17	
Tumors were isolated, minced in a petri dish on ice and then enzymatically dissociated 18	
in Hanks Balanced Salt Solution containing 0.5 mg/ml Collagenase IV (Sigma), 0.1 19	
mg/ml Hyaluronidase V (Sigma), 0.6 U/ml Dispase II (Roche) and 0.005 MU/ml DNAse I 20	
(Sigma) at 37°C for 5-30 min. The duration of enzymatic treatment was optimized for 21	
greatest yield of live CD11b+ cells per tumor type. Cell suspensions were filtered 22	
through a 70µm cell strainer. Red blood cells were solubilized with red cell lysis buffer 23	
		 22	
(Pharm Lyse, BD Biosciences, San Jose, CA), and the resulting suspension was filtered 1	
through a cell strainer to produce a single cell suspension. Cells were washed one time 2	
with PBS prior to use in flow cytometry analysis or magnetic bead purification.  3	
 4	
Peritoneal Macrophage Isolation 5	
Thioglycollate elicited peritoneal macrophages were collected 96h after i.p. injection of a 6	
3% thioglycollate solution. Cells were harvested from the peritoneal cavity in 10ml of 7	
PBS and macrophage enrichment was performed by plating cells in RPMI with 10% 8	
FBS and 1% pen/strep for 2h at 37C 5% CO2. After 2h, nonadherent cells were 9	
removed with three PBS washes, and cells were analyzed via flow cytometry and qPCR 10	
analysis.  11	
 12	
Flow cytometry staining and analysis 13	
Single cell suspensions (10^6 cells in 100 µL total volume) were incubated with Aqua 14	
Live Dead fixable stain (Life Technologies, Carlsbad, CA), FcR-blocking reagent (BD 15	
Biosciences, San Jose, CA) and fluorescently labeled antibodies and incubated at 4°C 16	
for 1h. Primary antibodies to cell surface markers directed against F4/80 (BM8), CD45 17	
(30-F11), CD11b (M1/70), Gr1 (RB6-8C5), CD3 (145-2C11), CD4 (GK1.5), CD8 (53-18	
6.7), CD273 (B7-DC), CD274 (B7-H1) were from eBioscience; Ly6C (AL-21), Ly6G 19	
(1A8), CD11c (HL3), and MHC-II (AF6-120.1) from BD Pharmingen, CCR2 (475301) 20	
from R&D Systems and CD206 (MR5D3) from AbD Serotech. For intracellular staining, 21	
cells were fixed, permeabilized using Transcription Factor Staining Buffer Set 22	
(eBioscience) and then incubated with fluorescently labeled antibodies to FoxP3 (FJK-23	
		 23	
16s) from eBioscience. Multicolor FACS Analysis was performed on a BD Canto RUO 1	
11 Color Analyzer. All data analysis was performed using the flow cytometry analysis 2	
program FloJo (Treestar).  3	
 4	
Magnetic bead purification of myeloid cells  5	
Single cell preparations from bone marrow or tumors were incubated with FcR-blocking 6	
reagent (BD Biosciences) and then with 20µl magnetic microbeads conjugated to 7	
antibodies against CD11b, Gr1, CD90.2, CD4 and CD8 (Miltenyi Biotech MACS 8	
Microbeads)/1xE7 cells for 20 min at 4°C. Cells bound to magnetic beads were then 9	
removed from the cell suspension according to manufacturers instructions. 10	
 11	
Flow cytometric sorting of cells from tumors and bone marrow 12	
For cell sorting, single cell suspensions were stained with Aqua Live Dead fixable stain 13	
(Life Technologies) to exclude dead cells and anti-CD11b-APC (M1/70, eBioscience) 14	
and anti-Gr1-FITC (RB6-8C5, eBioscience) antibodies. FACS sorting was performed on 15	
a FACS Aria 11 color high speed sorter at the Flow Cytometry Core at the UC San 16	
Diego Center for AIDS Research. Live cells were sorted into the following populations: 17	
CD11b+Gr1-, CD11b+Gr1lo, CD11b+Gr1hi and CD11b-Gr1- cells. CD11b positive cells 18	
were defined by increased staining over the isotype control, and Gr1 levels were 19	
defined both by comparison to the isotype control and relative staining to other 20	
populations. 21	
 22	
Murine macrophage differentiation and culture 23	
		 24	
Bone marrow derived cells (BMDC) were aseptically harvested from 6-8 week-old 1	
female mice by flushing leg bones of euthanized mice with phosphate buffered saline 2	
(PBS), 0.5% BSA, 2mM EDTA, incubating in red cell lysis buffer (155 mM NH4Cl, 10 3	
mM NaHCO3 and 0.1 mM EDTA) and centrifuging over Histopaque 1083 to purify the 4	
mononuclear cells. Approximately 5X107 BMDC were purified by gradient centrifugation 5	
from the femurs and tibias of a single mouse. Purified mononuclear cells were cultured 6	
in RPMI + 20% serum + 50ng/ml M-CSF (PeproTech).  7	
 8	
Human macrophage differentiation and culture 9	
Human leukocytes concentrated by from apheresis were obtained from the San Diego 10	
Blood Bank. Cells were diluted in phosphate buffered saline (PBS), 0.5% BSA, 2mM 11	
EDTA, incubated in red cell lysis buffer (155 mM NH4Cl, 10 mM NaHCO3 and 0.1 mM 12	
EDTA) and centrifuged over Histopaque 1077 to purify mononuclear cells. 13	
Approximately 109 BMDC were purified by gradient centrifugation from one apheresis 14	
sample. Purified mononuclear cells were cultured in RPMI + 20% serum + 50ng/ml 15	
Human M-CSF (PeproTech). Non-adherent cells were removed after 2h by washing, 16	
and adherent cells were cultured for 6 days to differentiate macrophages fully.  17	
 18	
Macrophage polarization 19	
Bone marrow derived macrophages were polarized with either IFNγ (20 ng/ml, 20	
Peprotech) plus LPS (100 ng/ml, Sigma) or LPS alone for 24h or IL-4 (20 ng/ml, 21	
Peprotech) for 24-48h. For inhibitor studies, PI3Kγ inhibitors (1 µM) (IPI-549, Infinity 22	
Pharmaceuticals and TG100-115, Targegen/Sanofi-Aventis), rapamycin (10 µM) 23	
		 25	
(Selleck), or ML120B (30 µM) were incubated with macrophages 1h prior to the addition 1	
of polarizing stimuli. Total RNA was harvested from macrophages using the RNeasy 2	
Mini Kit (Qiagen) according to the manufacture’s instructions.  3	
 4	
RNA sequencing 5	
Freshly isolated mouse bone marrow cells from 9 WT and 9 p110γ-/- mice were pooled 6	
into 3 replicates sets of WT or p110g-/- cells and differentiated into macrophages for six 7	
days in RPMI + 20% FBS+ 1%Pen/Strep+ 50 ng/ml M-CSF. Each replicate set of 8	
macrophages was then treated with mCSF, IL-4 or IFNg/LPS. Macrophages were 9	
removed from dishes, and RNA was harvested using Qiagen Allprep kit.  In addition, 10	
RNA was harvested from day 14 (500mm3) LLC tumors or purified CD11b+Gr1-F480+ 11	
TAMs from WT (C57BL/6) and p110γ-/- null mice. RNA was harvested using Qiagen 12	
Allprep kit. RNA libraries prepared from 1 µg RNA per sample were prepared for 13	
sequencing using standard Illumina protocols. RNA sequencing was performed by the 14	
University of California, San Diego Institute for Genomic Medicine. mRNA profiles were 15	
generated by single read deep sequencing, in triplicate, using Illumina HiSeq2000.   16	
 17	
Sequence analysis 18	
Sequence analysis was performed as previously described.15 Sequence files from 19	
Illumina HiSeq that passed quality filters were aligned to the mouse transcriptome (mm9 20	
genome build) using the Bowtie2 aligner4. Gene-level count summaries were analyzed 21	
for statistically significant changes using DESeq. Individual p-values were adjusted for 22	
multiple testing by calculating Storey's q-values using fdrtooltrimmer. For each gene, the 23	
		 26	
q-value is the smallest false discovery rate at which the gene is found significant. We 1	
analyzed biological processes as defined by the Gene Ontology Consortium. Each gene 2	
ontology term defines a set of genes. The entire list of genes, sorted by the q-value in 3	
ascending order, is subjected to a non-parametric variant of the Gene Set Enrichment 4	
Analysis (GSEA), in which the parametric Kolmogorov-Smirnov p-value is replaced with 5	
the exact rank-order p-value.  We perform a Bonferroni adjustment of gene set p-values 6	
for the number of gene sets tested. Heatmaps of expression levels were created using 7	
in-house hierarchical clustering software that implements Ward clustering. The colors 8	
qualitatively correspond to fold changes. Complete sequence data can be observed at 9	
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=yfwtskeirrefbsp&acc=GSE58318 10	
(in vitro macrophage samples) 11	
 and 12	
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=kpqnqyqalfgnlgd&acc=GSE84535 13	
(in vivo tumor and tumor associated macrophages samples). 14	
 15	
Individual quantitative RT-PCR 16	
cDNA was prepared using 1µg RNA with the qScript cDNA Synthesis Kit (Quanta 17	
Biosciences). Sybr green-based qPCR was performed using human and murine primers 18	
to Arg1, Ifng, Il10, Il12p40, Il1b, Il6, Ccl2, Vegfa, Gapdh, Nos2, Tgfb1, Tnfa and murine 19	
H2-Aa, H2-Ab1, H2-Eb1, and H60a (Qiagen QuantiTect Primer Assay). mRNA levels 20	
were normalized to Gapdh (dCt = Ct gene of interest – Ct Gapdh) and reported as 21	
relative mRNA expression (ddCt = 2^-(dCt sample – dCt control)) or fold change.  22	
 23	
		 27	
siRNA mediated knockdown and gene transfection 1	
Freshly isolated bone marrow derived CD11b+ myeloid cells or differentiated 2	
macrophages were transfected by electroporation using an AMAXA Mouse Macrophage 3	
Nucleofection Kit with 100nM of siRNA or 2µg p110gCAAX or pcDNA control plasmid. 4	
Non-silencing (Ctrl_AllStars_1), Cebpb (MmCebpb_4 and MmCebpb_6), Mtor 5	
(Mm_Frap1_1 and Mm_Frap1_2) were purchased from Qiagen. After transfection, cells 6	
were cultured for 36-48 h in RPMI containing 10% serum and 10ng/ml M-CSF 7	
(PeproTech) or polarized as described above.  8	
 9	
ELISA assays 10	
Whole tumors, CD11b+Gr1- cells, CD90.2+ cells, CD4+ cells and CD8+ cells isolated 11	
from LLC tumors were lysed in RIPA buffer and total protein concentration was 12	
determined using a BCA Protein Assay (Pierce). Macrophage supernatants (100 µl) or 13	
500 µg of total protein lysate from tumors were used in ELISAs to detect CCL2, TGFβ, 14	
IL-1β, TNFα, IL-6, IFNγ, IL-10, IL-12 and Granzyme B (Ready Set Go ELISA, 15	
eBioscience). Protein expression was normalized to total volume (supernatants) or mg 16	
total protein (tumor lysates). 17	
 18	
Quantitative Colorimetric Arginase Determination 19	
The QuantiChrom Arginase Assay Kit (DARG-200, BioAssay Systems) was used to 20	
measure Arginase activity in primary murine bone marrow derived macrophages from 21	
wildtype and p110γ-/- mice according to manufacturer’s instructions. For all conditions, 22	
cells were harvested and lysed in 10 mM Tris (pH7.4) containing 1 µM pepstatin A, 1 23	
		 28	
µM leupeptin, and 0.4% (w/v) TritonX-100. Samples were centrifuged at 20,000g at 4°C 1	
for 10 min.  2	
 3	
Transcription Factor Assays 4	
To measure NFκB and C/EBPβ activation, TransAM NFκB Family and C/EBPa/b 5	
Transcription Factor Assay Kits (43296 and 44196, Active Motif, Carlsbad, CA) were 6	
used according to manufacturer’s protocol. Briefly, wild type and p110γ-/- bone marrow 7	
derived macrophages were stimulated with LPS (100 ng/ml) or IL-4 (20 ng/ml) and 8	
nuclear extracts were prepared in lysis buffer AM2. Nuclear extracts were incubated 9	
with the immobilized consensus sequences and RelA, cRel or C/EBPβ were detected 10	
using specific primary antibodies. Quantification was performed via colorimetric readout 11	
of absorbance at 450 nm.  12	
 13	
Immunoblotting 14	
IL-4 and LPS macrophage cultures were solubilized in RIPA buffer containing protease 15	
and phosphatase inhibitors. Thirty µg protein was electrophoresed on Biorad precast 16	
gradient gels and electroblotted onto PVDF membranes. Proteins were detected by 17	
incubation with 1:1000 dilutions of primary antibodies, washed and incubated with Goat 18	
anti-rabbit-HRP antibodies and detected after incubation with a chemiluminescent 19	
substrate. Primary antibodies directed against Akt (11E7), p-Akt (244F9), IkBa (L35A5), 20	
IKKb (D30C6), p-IKKa/b (16A6), NFkBp65 (D14E12), pNFkBp65 (93H1), C/EBPb 21	
(#3087), p-CEBPb (#3082), IRAK1 (D51G7), TBK1 (D1B4), and p110γ (#4252) were 22	
from Cell Signaling Technology and pTBK1 (EPR2867(2)) was from Abcam. 23	
		 29	
 1	
In vitro cytotoxicity assay 2	
CD90.2+ tumor derived T cells were purified from LLC tumor-bearing WT and p110γ-/- 3	
or TG100-115 and control treated mice and then co-incubated with LLC tumor cells 4	
(target cells) at 2.5:1, 5:1 and 10:1 ratios of T cells to tumor cells (2x103 LLC tumor cells 5	
per well) for 6 hours. Target cell killing was assayed by collecting the supernatants from 6	
each well for measurement of the lactate dehydrogenase release (Cytotox96 Non 7	
Radioactive Cytotoxicity Assay kit, Promega). 8	
 9	
Immunohistochemistry 10	
Tumor samples were collected and cryopreserved in O.C.T. Sections (5µm) were fixed 11	
in 100% cold acetone, blocked with 8% normal goat serum for 2 hours, and incubated 12	
anti-CD8 (53-6.7, 1:50 BD Biosciences) for 2 hours at room temperature. Sections were 13	
washed 3 times with PBS and incubated with Alexa594-conjugated secondary 14	
antibodies. Slides were counterstained with 4',6-diamidino-2-phenylindole (DAPI) to 15	
identify nuclei. Immunofluorescence images were collected on a Nikon microscope 16	
(Eclipse TE2000-U) and analyzed using Metamorph image capture and analysis 17	
software (Version 6.3r5, Molecular Devices). The detection of apoptotic cells was 18	
performed using a TUNEL-assay (ApopTag Fluorescein In Situ Apoptosis Detection Kit, 19	
Promega) according to manufacturer’s instructions. Slides were washed and mounted in 20	
DAKO fluorescent mounting medium. Immunofluorescence images were collected on a 21	
Nikon microscope (Eclipse TE2000-U) and analyzed with MetaMorph Software (version 22	
		 30	
6.3r5) or SPOT software (version 4.6). Pixels/field or cell number/field were quantified in 1	
five 100x fields from 10 biological replicates. 2	
 3	
Statistics 4	
Primary tumor samples with mRNA expression data were scored as above or below the 5	
median expression level, and tested for association with patient survival using a logrank 6	
test at 5% significance. For studies evaluating the effect of drugs on tumor size, tumor 7	
dimensions were measured directly before the start of treatment, tumor volumes were 8	
computed and mice were randomly assigned to groups so that the mean volume +/- 9	
s.e.m. of each group was identical. A sample size of 10 mice/group provided 80% 10	
power to detect mean difference of 2.25 standard deviation (SD) between two groups 11	
(based on a two-sample t-test with 2-sided 5% significance level). Sample sizes of 15 12	
mice/group provided 80% power to detect one SD difference between two groups. Data 13	
were normalized to the standard (control). Significance testing was performed by one-14	
way Anova with Tukey's posthoc testing for multiple pairwise testing with more than two 15	
groups and by parametric or nonparametric Student’s t test when only two groups were 16	
compared. We used a two-sample t-test (two groups) and ANOVA (multiple groups) 17	
when data were normally distributed and a Wilcoxon rank sum test (two groups) when 18	
data were not normally distributed. All mouse studies were randomized and blinded; 19	
assignment of mice to treatment groups, tumor measurement and tumor analysis was 20	
performed by coding mice with randomly assigned mouse number, with the key 21	
unknown to operators until experiments were completed. In tumor studies for which 22	
tumor size was the outcome, animals removed from the study due to health concerns 23	
		 31	
were not included in endpoint analyses. All experiments were performed at least twice; 1	
n refers to biological replicates.   2	
		 32	
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Extended Data Figure 1: Pro-inflammatory gene expression signatures predict 1	
survival in cancer patients 2	
(a-e) Expression levels of IL12A, IL12B, IFNG, and CD8A, and IL6 associated with 3	
survival in HPV+ HNSCC patients. (f) Multivariate immune signature for 720 lung 4	
adenocarcinoma patients from KM plotter cohorts. (g) Multivariate immune signature in 5	
876 gastric cancer samples from KM plotter cohorts. (h) Western blotting to detect 6	
PI3Kγ (p110γ) in B cells, T cells, macrophages (MΦ) and LLC, PyMT and MEER tumor 7	
cells. (i) Kaplan Meier survival plot of WT and p110γ-/- mice inoculated with LPS 8	
(endotoxin). (j) Pro-inflammatory cytokine mRNA expression in bone marrow from WT 9	
and p110γ/- LPS injected animals (n=4, **p<0.001, **p<0.0001). (k) Circulating 10	
inflammatory cytokine levels in p110γ-/- and WT mice 24h after endotoxin administration 11	
(n=4, *p<0.01, **p<0.001). (l) Tumor volume of HPV- (SCCVII) head and neck (n=15) 12	
carcinomas from vehicle or PI3Kγ inhibitor-treated mice. Arrow, start of drug treatment. 13	
(m) Dose response of the effect of PI3Kγ inhibitor IPI549 on in vitro MEER cell viability. 14	
(n) Spontaneous PyMT lung metastases per high power field (200X) in WT and p110γ-/- 15	
animals (n=8). (o) Kaplan Meier survival plot of mice bearing orthotopic PyMT tumors 16	
treated with vehicle or PI3Kγ inhibitor IPI549 initiated as indicated by arrow (n=10). (p) 17	
In vitro LLC tumor cell survival in the presence of gemcitabine. (q) Volume of LLC 18	
tumors implanted in WT and p110γ-/- animals treated with saline or gemcitabine (n=10, 19	
**p<0.001, **p<0.01).  20	
 21	
  22	
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Extended Data Figure 2: Effect of PI3Kγ  inhibition on tumor inflammation 1	
(a) Gating strategy for flow cytometric analysis of myeloid cell populations in peripheral 2	
blood leukocytes. (b) Representative flow cytometric analysis and quantification of 3	
myeloid cell populations in peripheral blood (PB) of naïve and LLC tumor bearing mice 4	
(n = 3). (c) Flow cytometric analysis of myeloid cell populations on days 0, 7, 14 and 21 5	
after subcutaneous inoculation with Lewis lung carcinoma cells (n= 3). (d) Quantification 6	
of populations from c. (e) Flow cytometric analysis of Ly6G, CCR2, CX3CR1, CD206, 7	
CD11c, F4/80 and CD45 expression on myeloid cell populations from c (n=3). (f) 8	
Relative immune response transcript levels in tumor-derived myeloid cells and tumor 9	
cells (CD11b-Gr1- cells) isolated at day 0 (n=3), d7 (n=5), d14 (n=3) or d21 (n=4) after 10	
LLC cell inoculation (p < 0.002, d21 vs d0). (g) Flow cytometric analysis of CD11b+ 11	
myeloid cell populations in WT and p110γ-/- LLC, PyMT and MEER tumors (n=3). (h) 12	
Quantification of CD11b+ myeloid cell populations from (g). (i) Flow cytometric analysis 13	
of CD11b+ myeloid cell populations in vehicle and PI3Kγ inhibitor treated PyMT, MEER 14	
and SCCVII tumors (n=3). (j). Quantification of CD11b+ myeloid cell populations from 15	
(i).  16	
  17	
		 37	
Extended Data Figure 3: Effect of PI3Kγ  inhibition on TAM expression profile 1	
(a) Heatmap of differentially expressed immune response genes in TAMs isolated from 2	
LLC tumors from WT and p110γ-/- mice (n=3, *p<0.01, lfdr <0.1) obtained by RNA 3	
sequencing. (b) Relative mRNA expression of immune response factors in HPV+ 4	
HNSCC MEER tumors from p110γ-/- and WT mice (n=4), *p=0.01. (c) Relative mRNA 5	
expression of immune response factors in CD11b+ myeloid cells isolated from PyMT 6	
tumors grown in vehicle or PI3Kγ inhibitor-treated mice (n=4), *p=0.01. (d) Fold change 7	
in mRNA expression in CD11b+Gr1- (macrophage), CD11b+Gr1lo (monocytic) and 8	
CD11b+Gr1hi (granulocytic) myeloid cells isolated from LLC tumors grown in p110γ-/- 9	
mice (n=5) and normalized to WT control (n=5), p=0.001. (e) Arginase activity in tumors 10	
and TAMs isolated from LLC tumors grown in WT and p110γ-/- mice (n=4, ***p<0.0003). 11	
(f) Protein expression of cytokines in LLC tumors and TAMs from WT and p110γ-/- mice 12	
(n=4, *p<0.01, **p<0.001, ***p<0.0001).  13	
 14	
  15	
		 38	
Extended Data Figure 4: Effect of PI3Kγ  deletion on in vitro macrophage mRNA 1	
expression 2	
(a) Relative immune response mRNA expression in p110γ-/- and WT murine 3	
macrophages stimulated by IL-4 or LLC tumor cell conditioned medium (TCM) as 4	
determined by RT-PCR (n=3, *p=0.01). (b) Heat map of differentially expressed immune 5	
response transcripts in IL-4 and IFNγ/LPS polarized murine macrophages obtained by 6	
RNA sequencing (n=3, p=0.00001). (c) Heat map of select differentially expressed 7	
immune response transcripts in in vitro polarized murine macrophages (n=3, 8	
p=0.00001). (d) Heat map of immune response transcripts in mCSF, IL-4 and IFNγ/LPS 9	
stimulated p110γ-/- murine macrophages obtained by RNA sequencing and normalized 10	
to WT (n=3, p=0.00001). (e) Heat map of select differentially expressed immune 11	
response transcripts in polarized p110γ-/- murine macrophages normalized to WT (n=3, 12	
p=0.00001). (f) Heat map of differentially expressed antigen presentation and 13	
processing mRNAs in mCSF, IL-4 and IFNγ/LPS polarized p110γ-/- murine 14	
macrophages (n=3). (g) Heat map of differentially expressed chemokine and chemokine 15	
receptor mRNAs in polarized p110γ-/- murine macrophages (n=3).   16	
		 39	
Extended Data Figure 5: Effect of PI3Kγ  inhibition on murine and human 1	
macrophage polarization 2	
(a) Relative mRNA expression of immune response transcripts in IL-4 and IFNγ/LPS 3	
stimulated vehicle and PI3Kγ inhibitor (IPI-549) treated (a) murine and (b) human 4	
macrophages (n=3, p=0.001). (c) Relative mRNA expression of M2 macrophage 5	
markers (Arg1, Fizz1 and Ym1) in WT and p110γ-/- IL4-stimulated macrophages (n=3). 6	
(d) Relative expression of MHC family members in WT and p110γ-/- IL4-stimulated 7	
macrophages (n=3). (e-f) Time course of cytokine mRNA expression in IFNγ/LPS, LPS 8	
and IL-4 stimulated (e) WT vs p110γ-/- and (f) vehicle vs. PI3Kγ inhibitor (IPI-549)-9	
treated macrophages (n=3). (g) Relative mRNA expression in mCSF-stimulated WT vs 10	
p110γ-/- and IPI-549- vs vehicle-treated macrophages (n=3). (g) Relative nuclear RelA 11	
DNA binding activity in IFNγ/LPS stimulated WT and p110γ-/- macrophages (n=3).  12	
		 40	
Extended Data Figure 6: Mechanism of PI3Kγ  mediated gene expression 1	
regulation 2	
(a) Relative levels of phospho/total p65 and phospho/total C/EBPβ in LPS and IL-4 3	
stimulated WT and p110γ-/- macrophages. (b) Immunoblotting to detect pThr308Akt, 4	
total Akt, phospho-p65 and total p65 in LPS and IL-4 stimulated, macrophages that 5	
were treated with vehicle or the PI3Kγ inhibitor IPI-549. (c) Relative Arg1 mRNA 6	
expression in myeloid cells transfected with constitutively active, membrane-targeted 7	
PI3Kγ (p110γCAAX) and Mtor, S6ka, Cebpb or control siRNA (n=3). (d) Validation of 8	
siRNAs from c. (e) Effect of Cebpb, Mtor or S6ka siRNAs on gene expression in WT 9	
macrophages. (f-g) Effect of rapamycin (f) or S6K inhibitor (PF4708671) (g) on 10	
macrophage mRNA expression. (h) Immunofluorescence images of CD8+ T cells in 11	
10µm tumor sections from 3c. (i) Mean tumor volumes from tumor cells mixed with WT 12	
TAMs pretreated with the mTOR inhibitor Rapamycin or the Arginase inhibitor nor-13	
NOHA and p110γ-/- TAMs pretreated with anti-IL12 or isotype matched control antibody 14	
(cIgG), IKKβ inhibitor (MLB120) or  NOS2 inhibitor (1400W dihydrochloride) (n=10).  15	
		 41	
Extended Data Figure 7: No direct effect of PI3Kγ  inhibition on T cells  1	
(a) Volumes of LLC tumors treated with vehicle + control liposomes, PI3Kγ inhibitor (IPI-2	
549) + control liposomes, clodronate liposomes + vehicle and PI3Kγ inhibitor + 3	
clodronate liposomes (n=10). (b) Quantification of F4/80+ macrophages in tumors from 4	
a (n=3). (c) Quantification of F4/80+ macrophages in livers from a (n=3). (d) 5	
Quantification of T cells in tumors from a (n=3, *p<0.05). (e) Volumes of CT26 tumors 6	
treated with vehicle + cIgG, PI3Kγ inhibitor (IPI-549) + cIgG, anti-CD115 + vehicle and 7	
PI3Kγ inhibitor + anti-CD115 (n=15). (f) Quantification of CD11b+ myeloid cells in 8	
tumors from e (n=5). (g) Images and quantification of CD8+ T cells in WT and p110g-/- 9	
LLC tumors by IHC (n=5). (h) Flow cytometric analysis and quantification of T cell 10	
populations in tumors from WT and p110γ-/- or IPI-549 treated animals (n=3). (i) 11	
Quantification of T cells in spleens of naïve and LLC tumor-bearing WT and p110γ-/- 12	
mice (n=3). (j) Volumes of LLC lung tumors from WT, p110γ-/-, CD8-/- and CD8-/-; p110γ-/- 13	
animals (n=12). (k) LLC tumor volume from WT and p110γ-/- animals treated with anti-14	
CD8 antibodies or control (n=10) and percent CD8+ T cells in these tumors (n=3). (l) In 15	
vitro proliferation of T cells isolated from naïve and LLC tumor-bearing WT and p110γ-/- 16	
mice (n=3). (m) IFNγ and Granzyme B protein expression in T cells from l (n=3).   17	
		 42	
Extended Data Figure 8: PI3Kγ  inhibition relieves T cell exhaustion  1	
(a) Effect of PI3Kγ and PI3Kδ inhibitors on IFNγ expression by activated human T cells 2	
(n=3). (b) Mean weights of tumors derived from a mixture of LLC cells and WT or p110γ-3	
/- tumor derived T cells or WT T cells pre-incubated with 10 or 100 nM PI3Kγ (IPI-549) 4	
and PI3Kδ (Cal101) inhibitors prior to implantation (n=16). (c-d) In vitro LLC tumor cell 5	
cytotoxicity induced by T cells isolated from LLC tumors from (c) WT and p110γ-/- or (d) 6	
control- and PI3Kγ inhibitor-treated mice (n=3, *p<0.001). (e) Images of TUNEL and 7	
H&E stained tumors as described in Fig. 5c. (f) Quantification of TUNEL+ cells in tumor 8	
sections from e. (g) Mean tumor volumes in WT mice derived from LLC tumor cells 9	
mixed 1:1 with CD90.2+, CD4+ and CD8+ T cells or no T cells from WT or p110γ-/- 10	
tumor-bearing animals (n=8). (h) IL10 and TGFβ protein expression in lysates from 11	
tumor and CD90.2+, CD8+ and CD4+ T cells isolated from LLC tumors grown in WT 12	
and p110γ-/- animals (n=3). (i) Interferon gamma and Granzyme B protein expression in 13	
PI3Kγ inhibitor or control-treated LLC tumors (n=3). (j) Ifnγ and Tgfb1 mRNA expression 14	
in T cells isolated from LLC tumors grown in WT and p110γ-/- or control- and PI3Kγ 15	
inhibitor-treated mice (n=3). (k) Relative mRNA expression of Cd4, Cd8, Grzb and Ifng 16	
in control and PI3Kγ inhibitor treated PyMT tumors (n=3). (l) Relative mRNA expression 17	
of Cd4, Cd8, Grzb, and Ifng in WT and p110γ-/- and PI3Kγ inhibitor treated HPV+ MEER 18	
tumors (n=3).   19	
		 43	
Extended Data Figure 9: PI3Kγ  role in the macrophage-mediated tumor immune 1	
response  2	
(a-b) Flow cytometric analysis of PD-L1 and PD-L2 expression on (a) tumor cells and 3	
TAMs from WT and p110γ-/- LLC tumors and (b) WT and p110γ-/- in vitro cultured 4	
IFNγ/LPS- and IL4-stimulated macrophages (n=3). (c) HPV+ HNSCC tumor growth in 5	
female WT or p110γ-/- mice that were treated with anti-PD-1 or isotype matched 6	
antibody (cIgG), as indicated by arrows, and percent change in tumor volumes between 7	
days 11 and 23. (d) HPV+ HNSCC tumor growth in female WT mice that were treated 8	
with PI3Kγ inhibitor (2.5 mg/kg TG100-115 b.i.d). in combination with anti-PD-1 or 9	
isotype matched antibody (cIgG), as indicated by arrows, and percent change in tumor 10	
volumes 11 and 29. (e) HPV- HNSCC tumor growth in mice that were treated with PI3Kγ 11	
inhibitor (2.5 mg/kg TG100-115 b.i.d) in combination with anti-PD-1 cIgG, as indicated 12	
by arrows, and percent change in tumor volumes between days 19-26. (f) Tumor 13	
rechallenge in HPV+ mice that had cleared previously HPV+ tumors (n=7-12) vs WT 14	
mice (n=5). (g) Quantification of percent CD3, CD4+ and CD8+ T cells and MHCII+ 15	
macrophages from Figure 5l. (*p<0.05, **p<0.005, ****p<0.00005).  16	
		 44	
Extended Data Figure 10: PI3Kγ  promotes immune suppression. 1	
(a) Comparison of gene expression between HPV+ and HPV- cohorts indicating HPV- 2	
samples had significantly (p<0.05) lower expression of adaptive immune genes and 3	
higher expression of immune suppressive/pro-metastasis genes (Blue: HPV- samples, 4	
Red: HPV+ samples.) (b) Model depicting the effect of PI3Kγ inhibition on tumor 5	
immune suppression. PI3Kγ inhibition converts tumor-associated macrophages into pro-6	
inflammatory macrophages that promote a CD8+ T cell response that suppresses tumor 7	
growth. (c) Model depicting the PI3Kγ signaling pathway in macrophages. PI3Kγ 8	
activation restrains NFκB activation and promotes mTOR-dependent C/EBPβ activation, 9	
leading to expression of immune suppressive factors and tumor growth. In contrast, 10	
PI3Kγ inhibition inhibits C/EBPβ and stimulates NFκB, leading to altered expression of 11	
pro-inflammatory immune response cytokines. 12	
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